openPR Logo
Press release

Onychomycosis (Tinea Unguium) Global Key Players Almirall SA, Blueberry Therapeutics Ltd, Dermala Inc, Hexima Ltd Kaken, Pharmaceutical Co Ltd Market Analysis and Forecast 2018-2022

02-06-2018 11:30 AM CET | Health & Medicine

Press release from: WISE GUY RESEARCH CONSULTANTS PVT. LTD.

/ PR Agency: Wise Guy Research Consultants Pvt. Ltd
Onychomycosis (Tinea Unguium)

Onychomycosis (Tinea Unguium)

WiseGuyReports.com with their unique quality of simplifying the market research study presents a deep diving study report “Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2018”

Onychomycosis (Tinea Unguium)

Overview

Onychomycosis is a chronic fungal infection of the nails caused by dermatophytes. Symptoms include thickened nail that is difficult to cut, brittle or ragged nail, discolored or unsightly nail and pain of the finger or toe with ordinary activities. Treatment includes antifungal medications and surgery.

Onychomycosis which is also known as fungal infection of the nails is somewhat uncommon during childhood. After puberty, its frequency increases with age. Usually, Onychomycosis is associated with tinea pedis.

Click here for sample report @ https://www.wiseguyreports.com/sample-request/2811469-onychomycosis-tinea-unguium-pipeline-review-h1-2018

Onychomycosis (Tinea Unguium) Industry Major Highlights:

Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease), drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The report further guide in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Onychomycosis (Tinea Unguium) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Apart from this various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Major Outlook for Onychomycosis (Tinea Unguium) Report:

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Onychomycosis (Tinea Unguium) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Onychomycosis (Tinea Unguium) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Onychomycosis (Tinea Unguium)

The pipeline guide provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium).

- The pipeline guide reviews pipeline therapeutics for Onychomycosis (Tinea Unguium) by companies and universities/research institutes based on information derived from company and industry-specific sources.

Competitive Analysis for Onychomycosis (Tinea Unguium)

Key players are making innovative developments in Onychomycosis (Tinea Unguium) industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector.

The key players in this market are Almirall SA, Blueberry Therapeutics Ltd, Dermala Inc, Eisai Co Ltd, Helix BioMedix Inc, Hexima Ltd Kaken, Pharmaceutical Co Ltd, Meiji Seika Pharma Co Ltd, and Moberg. 

….. Continued

Table of Contents

Introduction 5

Global Markets Direct Report Coverage 5

Onychomycosis (Tinea Unguium) - Overview 6

Onychomycosis (Tinea Unguium) - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Products under Development by Companies 10

Onychomycosis (Tinea Unguium) - Therapeutics Assessment 11

Assessment by Target 11

Assessment by Mechanism of Action 13

Assessment by Route of Administration 15

Assessment by Molecule Type 17

Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development 19

ActiveSite Pharmaceuticals Inc 19

Coherus BioSciences Inc 19

Lupin Ltd 20

Mabion SA 20

....

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2811469-onychomycosis-tinea-unguium-pipeline-review-h1-2018

Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.

WISEGUY RESEARCH CONSULTANTS PVT LTD
Office No. 528, Amanora Chambers
Pune - 411028
Maharashtra, India

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Onychomycosis (Tinea Unguium) Global Key Players Almirall SA, Blueberry Therapeutics Ltd, Dermala Inc, Hexima Ltd Kaken, Pharmaceutical Co Ltd Market Analysis and Forecast 2018-2022 here

News-ID: 933039 • Views:

More Releases from WISE GUY RESEARCH CONSULTANTS PVT. LTD.

CBD Snack Market 2020- Global Industry Analysis, By Key Players, Segmentation, Trends and Forecast By 2026
CBD Snack Market 2020- Global Industry Analysis, By Key Players, Segmentation, T …
Summary: A new market study, titled “Discover Global CBD Snack Market Upcoming Trends, Growth Drivers and Challenges” has been featured on WiseGuyReports. Introduction “CBD Snack Market” COVID-19, the disease it causes, surfaced in late 2019, and now had become a full-blown crisis worldwide. Over fifty key countries had declared a national emergency to combat coronavirus. With cases spreading, and the epicentre of the outbreak shifting to Europe, North America, India and
Chronic Lymphocytic Leukemia Global Key Players 4SC AG, AbbVie Inc, Baliopharm AG, Celltrion Inc, Debiopharm International SA, Eli Lilly and Co, Market Analysis and Forecast 2017-2022
Chronic Lymphocytic Leukemia Global Key Players 4SC AG, AbbVie Inc, Baliopharm A …
WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2017” Chronic lymphocytic leukemia (CLL) Overview Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms usually develop slowly. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections
Non Alcoholic Fatty Liver Disease Global Key Players Akcea Therapeutics Inc, Betagenon AB, Cadila Healthcare Ltd, Daewoong Pharmaceutical Co Ltd, Eli Lilly and Co Market Analysis and Forecast 2018-2022
Non Alcoholic Fatty Liver Disease Global Key Players Akcea Therapeutics Inc, Bet …
WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2018” Non Alcoholic Fatty Liver Disease (NAFLD) Overview Non Alcoholic Fatty Liver Disease (NAFLD) this situation arise when individual have too much fats there your liver. There should be little or no fat in a healthy liver and for most people, carrying a small amount of
Primary Sclerosing Cholangitis Key Players : Acorda Therapeutics Inc, Conatus Pharmaceuticals Inc, Dr. Falk Pharma GmbH, Gilead Sciences Inc, NGM Biopharmaceuticals Inc, Noxopharm Ltd, and Sirnaomics Inc Market Analysis and Forecast 2018-2022
Primary Sclerosing Cholangitis Key Players : Acorda Therapeutics Inc, Conatus Ph …
WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Primary Sclerosing Cholangitis - Pipeline Review, H1 2018” Primary Sclerosing cholangitis (PSC) Overview Primary Sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain, chills, diarrhea, fatigue, itchiness and weight loss. The predisposing factors include

All 5 Releases


More Releases for Onychomycosis

Rising Diabetic Population Fuels Onychomycosis Market Growth: Powering Innovatio …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Onychomycosis Market Through 2025? In recent times, the onychomycosis market has experienced robust growth. It is projected to expand from $3.63 billion in 2024 to $3.83 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 5.4%. The growth seen in
Rising Diabetic Population Fuels Onychomycosis Market Growth: A Significant Driv …
The Onychomycosis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Onychomycosis Market Size and Projected Growth Rate? The market for onychomycosis has seen substantial growth in recent times. The market size is predicted to rise from $3.63 billion in 2024 to $3.83 billion
Onychomycosis Market Insights and Development Trends
The Onychomycosis Market Is Set To Grow At An Estimated CAGR Of 8.5% From 2025 To 2034, Rising From $7.8 Billion In 2024 To $14.5 Billion By 2034. On March 21, 2025, Exactitude Consultancy., Ltd. released a research report offers a comprehensive examination of the various processes and materials used in the production of Onychomycosis market goods. The market study excludes key regions that are accelerating marketization. This section also gives
Onychomycosis Treatment Market Size & Share Analysis
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033. Onychomycosis Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance. The Market Size Is Expected To Reach $4.73 billion In 2028 At
Onychomycosis Therapeutics Market - Empowering Nail Wellness, Inspiring Beautifu …
Newark, New Castle, USA - new report, titled Onychomycosis Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Onychomycosis Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Onychomycosis Therapeutics market. The report offers an overview of the market, which
Dermatophytic Onychomycosis Therapeutics (DOT) Market
Market growth is primarily driven by factors such as increase in the prevalence of fungal toe nail infections in the U.S. and Canada, and rising per capita healthcare expenditure across the globe. Easy application of nail paints is also expected to drive demand for dermatophytic onychomycosis drugs. However, adverse effects associated with anti-fungal drugs and lack of awareness about dermatophytic onychomycosis in Asia Pacific, Middle East and Africa, and Latin